Skip to content
Clinical Trials – home
Ipsen Innovation
Sponsor

Ipsen Innovation

France 70 Rue Balard, 75015 Paris, France

About the sponsor

Clinical research includes cervical dystonia, with attention to symptom control and functional improvement in adults affected by involuntary muscle contractions.

  • Cervical dystonia
  • Botulinum toxin-based therapy

Trials in this area reflect interest in neurological conditions involving abnormal muscle activity and impaired motor control.

About Specializations

Ipsen Innovation runs clinical trials in conditions such as Migraine, Skin wrinkling, Torticollis, Muscle spasticity, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Torticollis

Recruiting

Study on IPN10200 for Treating Cervical Dystonia in Adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Skin wrinkling

Recruiting

Study on the Safety and Effectiveness of IPN10200 and Botulinum Toxin Type A for Adults with Moderate to Severe Upper Facial Lines

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Migraine

Not recruiting

Study of IPN10200 compared to placebo for prevention of episodic or chronic migraine in adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Muscle spasticity

Not recruiting

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Episodic Migraine in Adults

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Chronic Migraine in Adults

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Skin wrinkling

Not recruiting

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.